Last reviewed · How we verify
NCT06880601: TALIM
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
Phase 2 trial testing Teclistamab in Multiple Myleoma in 52 participants. Not yet recruiting.
1 November 2029
Quick facts
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 1 November 2025 |
| Primary completion | 1 November 2029 |
| Estimated completion | 1 November 2029 |
Drugs / interventions tested
- Teclistamab (TECLISTAMAB) — full drug profile →
Conditions studied
- Multiple Myleoma — all drugs for Multiple Myleoma →
- Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
- Multiple Myeloma Refractory — all drugs for Multiple Myeloma Refractory →
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto — full company profile →
Who can join
18 and older, any sex, with Multiple Myleoma or Multiple Myeloma in Relapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the efficacy of Teclistamab (Te) and autologous lymphocyte infusions (ALI) in relapse refractory multiple myeloma. The main question it aims to answer is: which is the Duration of response (DoR) with Teclistmab and ALI? Participants will receive Te for 5 cycles. Participants in PR or better after the first five cycles of Te monotherapy will continue treatment with Te in combination with ALI administration starting from cycle 6
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06880601
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Teclistamab
Trials testing the same drug.
- NCT07463807 — Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carf · Phase 1, PHASE2 · not yet recruiting
- NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
- NCT07332507 — Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma · Phase 1 · not yet recruiting
- NCT06948084 — Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Darat · Phase 2 · not yet recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other recruiting trials for Multiple Myleoma
Currently open trials in the same condition.
- NCT06663046 — Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06952075 — GR1803 Injection in Patients With RRMM · Phase 2 · recruiting
Other Gruppo Italiano Malattie EMatologiche dell'Adulto trials
Trials by the same sponsor.
- NCT07356960 — Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world · not yet recruiting
- NCT07158294 — Identification of BCR::ABL1 Mutations by Digital PCR in CML · NA · not yet recruiting
- NCT07249606 — Momelotinib Effectiveness in Myelofibrosis · not yet recruiting
- NCT06657846 — HRQoL and Financial Toxicity in Patients With VEXAS Syndrome · recruiting
- NCT05613296 — Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06880601 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Malattie EMatologiche dell'Adulto
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06880601.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing